Stay updated with breaking news from Sci Communications. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Penumbra, Inc.
Oncocyte to Present at the 23rd Annual Needham Virtual Growth Conference Nachrichtenquelle: globenewswire | 13.01.2021, 00:21 | 131 | 0 IRVINE, Calif., Jan. 12, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the cancer care continuum, announced today that management is scheduled to present at the 23 rd Annual Needham Virtual ...
Share this article HOLON, Israel, Dec. 23, 2020 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced today progress from its ongoing license agreement with AstraZeneca (LSE: AZN) (STO: AZN) (NASDAQ: AZN) under which the program has achieved a preclinical milestone. Under the terms of the agreement, Compugen provided an exclusive license to AstraZeneca for the development of bispecific and multi-specific antibody products based on one of Compugen's pipeline programs, with AstraZeneca responsible for ...
Press release content from Globe Newswire. The AP news staff was not involved in its creation. Ziopharm Oncology Announces Clearance of Taiwan’s First IND of Non-viral CAR-T for the ... ZIOPHARM Oncology IncDecember 21, 2020 GMT – Advances Eden BioCell’s clinical program to validate Rapid Personalized Manufacturing (RPM) – – Clinical trial to study autologous CD19-specific CAR-T using RPM technology designed to reduce cost and simplify production for infusion the day after gene transfer – BOSTON, Dec. 21, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or “the C...
Press release content from Globe Newswire. The AP news staff was not involved in its creation. Athenex Announces FDA Approval of Klisyri® (Tirbanibulin) for the Treatment of Actinic ... Athenex, Inc.December 15, 2020 GMT Klisyri is the first FDA approved proprietary product for Athenex First-in-class microtubule inhibitor indicated for the topical treatment of actinic keratosis (AK) on the face or scalp with a 5-day application course Klisyri will be manufactured by Athenex Almirall will launch Klisyri in the U.S. in first quarter 2021 BUFFALO, N.Y., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Athenex...